Advisor Group Holdings, Inc. Nurix Therapeutics, Inc. Transaction History
Advisor Group Holdings, Inc.
- $42.1 Billion
- Q1 2025
A detailed history of Advisor Group Holdings, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,275 shares of NRIX stock, worth $15,478. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,275
Previous 816
56.25%
Holding current value
$15,478
Previous $15,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$82.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$66.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$53.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$49.2 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$48.3 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $572M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...